Serevent (salmeterol xinafoate) Jan 2003
Audience: Pulmonary specialists and other healthcare professionals
GlaxoSmithKline notified healthcare professionals of important new safety information on use of Serevent in patients with asthma. Recent findings from an interim analysis of a large Serevent safety study have prompted further review of the potential association between Serevent and rare, but potentially serious, respiratory adverse events.
[January 23, 2003 - Letter - FDA]